ABSTRACT
OBJECTIVES: The aim of this study was to adapt the "Neuropathic Pain Impact on Quality-of-Life Questionnaire" (NePIQoL) into Turkish and to test its validity and reliability in neuropathic pain patients. METHODS: We enrolled 200 chronic pain patients who admitted to the Neurology Department of Kirikkale University, Faculty of Medicine, in our study. Patients were diagnosed with neuropathic or nociceptive pain based on medical history, physical examination, electromyography and nerve conduction studies, laboratory examinations, and imaging techniques. Discriminant analysis was used to diagnose the neuropathic pain regarding sensitivity and specificity. The original version of the NePIQoL was translated into Turkish by standard procedures. RESULTS: Total NePIQoL scores were statistically different between neuropathic and nociceptive pain patients in both the first and second NePIQoL applications (P < 0.001). Cronbach's alpha coefficient of total 12 items of the first and second applications was 0.95. These results suggest a high validity level for the Turkish version of the NePIQoL. CONCLUSIONS: The Turkish version of NePIQoL appears to be reliable and valid for neuropathic pain impact on quality of life in patients with neuropathic pain.
Subject(s)
Neuralgia/diagnosis , Quality of Life , Surveys and Questionnaires , Translations , Adult , Chronic Pain/diagnosis , Female , Humans , Language , Male , Middle Aged , Physical Examination , Reproducibility of Results , Sensitivity and Specificity , TurkeyABSTRACT
OBJECTIVE: The Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) is a 7-item self-report scale developed to identify pain of predominantly neuropathic origin. The aim of this study was to develop a Turkish version of the S-LANSS and to test its validity and reliability in chronic pain patients. METHOD AND PATIENTS: We enrolled 244 chronic pain patients treated at the Neurology Department. The original version of the S-LANSS was translated into Turkish by standard procedures. An independent clinician determined the pain type (neuropathic vs nociceptive). The reliability (internal consistency and test-retest reliability) and validity (agreement with the reference diagnosis and sensitivity, specificity, and positive and negative predictive values) were determined. RESULTS: Two-hundred and forty-four patients with chronic pain (167 women, 43.1 +/- 11.4 years), 137, neuropathic pain and 107, nociceptive pain, were asked to complete the S-LANSS twice. Cronbach's alpha-coefficient was 0.74 for the test and 0.73 for the retest. Total S-LANSS scores for subjects did not significantly differ between applications (P = 0.46). Correlation coefficient was r: 0.97 (P < 0.01), which is fairly high for a self-assessment tool. Compared with the clinical assessment, the sensitivity and specificity of the S-LANSS were 72.3% (95% CI, 64.0-79.6%) and 80.4% (95% CI, 71.6-87.4%), respectively, for both the test and retest. The sensitivity and specificity of the Turkish S-LANSS were similar to those determined in the original validation study. CONCLUSION: This study reports the first validation of a translated version of the S-LANNS into another language. The results suggest that the Turkish version of S-LANSS is a reliable and valid differential diagnostic measure of neuropathic pain in chronic pain patients.
Subject(s)
Chronic Disease , Language , Neuralgia/physiopathology , Pain Measurement , Self-Assessment , Surveys and Questionnaires , Adult , Female , Humans , Male , Middle Aged , Pain Measurement/methods , Pain Measurement/statistics & numerical data , Reproducibility of Results , Sensitivity and Specificity , Surveys and Questionnaires/standardsABSTRACT
BACKGROUND: Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy caused by median nerve compression at the wrist. It results in loss of considerable man days and the effectiveness the various treatment modalities are still debated. AIM: To study the efficacy of gabapentin in patients with CTS. The study aim is to investigate the efficacy of gabapentin in patients with CTS patients who were refractory to the other conservative measures or unwilling for the surgical procedure. MATERIALS AND METHODS: Forty one patients diagnosed as idiopathic CTS were included in the study. Patients were assessed with symptom severity scale (SSS) and functional status scale (FSS) scores of Boston Carpal Tunnel Questionnaire (BCTQ) before and at 1, 3, and 6 months of the treatment. Response to therapy was determined by using SSS and FSS scores of BCTQ. RESULTS: The median dosage of gabapentin was 1800 mg/daily. Side effects were mild and transient. There was a statistically significant difference in both symptom SSS and FSS scores between before and after treatment in patient groups at the end of six months (P < 0.001). According to grading the changes in subscales of BCTQ, of 41 patients, 34.1 and 29.3 had a >or= 40% decrease in SSS and FSS, respectively. CONCLUSION: Gabapentin was found to be partially effective and safe in symptomatic treatment of CTS patients.
Subject(s)
Amines/therapeutic use , Anticonvulsants/therapeutic use , Carpal Tunnel Syndrome/drug therapy , Cyclohexanecarboxylic Acids/therapeutic use , gamma-Aminobutyric Acid/therapeutic use , Adult , Female , Follow-Up Studies , Gabapentin , Humans , Male , Middle Aged , Severity of Illness Index , Surveys and Questionnaires , Young AdultABSTRACT
To evaluate brainstem excitability in menstrual migraine (MM) patients and compare the electrophysiological parameters of the trigeminocervical reflex (TCR) during the perimenstrual (headache period) and follicular (headache-free) periods with those in healthy controls. Thirty-one patients with MM and 22 volunteer age- and sex-matched healthy women were included in the study. The TCR was studied bilaterally with stimulation of the supraorbital branch of the trigeminal nerve during the perimenstrual period and follicular phase. The electrophysiological parameters of the TCR were compared between MM patients and controls. In controls, there was no statistically significant difference in the mean reflex latencies recorded during the perimenstrual and follicular phases (P > 0.05). In MM patients, the mean reflex latencies recorded during the perimenstrual (headache period) and follicular phase (headache-free) periods were significantly different from each other and from those in controls. The latencies of MM patients during the follicular (headache-free) period were significantly longer than those of controls. Brainstem excitability differed significantly between the perimenstrual (headache period) and follicular phase (headache-free) periods in MM. Furthermore, trigeminal excitability in MM patients was significantly different from that in healthy controls in both phases of the menstrual period.
Subject(s)
Menstrual Cycle/physiology , Menstruation Disturbances/physiopathology , Migraine Disorders/physiopathology , Pain Threshold/physiology , Trigeminal Nerve/physiopathology , Adult , Afferent Pathways/physiopathology , Brain Stem/physiopathology , Electric Stimulation , Electrodiagnosis/methods , Female , Humans , Menstruation Disturbances/complications , Middle Aged , Migraine Disorders/etiology , Neck Muscles/innervation , Neck Muscles/physiopathology , Neural Conduction/physiology , Neuralgia/diagnosis , Neuralgia/etiology , Neuralgia/physiopathology , Ophthalmic Nerve/anatomy & histology , Ophthalmic Nerve/physiology , Pain Measurement/methods , Reaction Time/physiology , Reflex/physiology , Trigeminal Nuclei/physiopathology , Young AdultABSTRACT
The objective of this study was to investigate the long-term efficacy and safety of botulinum toxin type-A (BoNT-A) for refractory chronic tension-type headache (CTTH). An open-label, prospective study was carried out in the Department of Neurology of Kirikkale University on 28 patients (8 males, 20 females), mean age 35.6 years, diagnosed with moderate/severe CTTH refractory to preventive medications. Each patient received BoNT-A injections once in pericranial muscles. Efficacy and safety data were analysed for 28 refractory CTTH patients who were receiving concomitant headache prophylactic medications at baseline and during the study. The main outcome parameters were reduction of headache frequency and intensity over 1 year. Both parameters were significantly decreased (p<0.05) by the end of the study. Sixty-four percent of patients reported complete headache relief at the final visit, compared to 7% CTTH persisted. BoNT-A also resulted in significant reductions in analgesic consumption (p<0.05). Adverse effects were transient and local. BoNT-A was found to be an effective and safe treatment for refractory CTTH patients with concomitant headache prophylactic medications, resulting in significant reductions in headache frequency, intensity and analgesic consumption which persisted up to 1 year.
Subject(s)
Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/adverse effects , Muscle, Skeletal/drug effects , Tension-Type Headache/drug therapy , Adult , Analgesics/therapeutic use , Chronic Disease , Female , Humans , Male , Middle Aged , Muscle, Skeletal/physiopathology , Neck Muscles/drug effects , Neck Muscles/physiopathology , Neuromuscular Agents/administration & dosage , Neuromuscular Agents/adverse effects , Patient Satisfaction , Prospective Studies , Recurrence , Tension-Type Headache/physiopathology , Time , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: Both basic and clinical research has demonstrated that antiepileptic drugs can be effective in alleviating neuropathic pain. It was hypothesized that oxcarbazepine might be effective in reducing the symptoms of painful diabetic neuropathy. AIMS: To investigate the long-term efficacy and safety of oxcarbazepine in symptoms of painful diabetic neuropathy. MATERIALS AND METHODS: This study included thirty-eight painful diabetic neuropathy patients, which were screened with clinical assessment and electrophysiological studies. The efficacy and safety of oxcarbazepine were evaluated according to the changes in pain intensity and social interference subitems scores of Short-form Brief Pain Inventory besides electrophysiological studies at the end of six months of the treatment. STATISTICAL ANALYSIS: The Students t, Mann-Whitney U and Rank Sum test and Chi-square tests were applied to examine variables differences. The level of statistical significance was chosen to be P<0.05. RESULTS: A significant difference was found in all of subitems of pain intensity and social interference at the end of the study according to the baseline scores. Improvement was observed in 52.7%, 63.1%, 55.3% and 63.2% of patients for worst, least, average and pain right now at the end of six months, respectively. Improvement was observed as 60.6%, 63.2%, 52.6%, 60.5%, 68.4% and 63.2% for general activity, mood, walk, work, people relations, sleep and life enjoyment subitems, respectively. None of these patients had any prominent side effect leading to discontinue the treatment. CONCLUSION: Long-term oxcarbazepine treatment was found to be effective and safe in the symptoms of painful diabetic neuropathy.
Subject(s)
Carbamazepine/analogs & derivatives , Diabetic Neuropathies/drug therapy , Adolescent , Adult , Aged , Carbamazepine/adverse effects , Carbamazepine/therapeutic use , Diabetes Mellitus, Type 2 , Female , Humans , Male , Middle Aged , Oxcarbazepine , Pain/drug therapy , Pain/etiology , Pain MeasurementABSTRACT
A unique case of bilateral severe carpal tunnel syndrome due to familial Mediterranean fever is reported. The syndrome was diagnosed by clinical examination and electrophysiological studies. Bilateral transverse carpal ligaments were released and the biopsy specimens revealed systemic type A amyloidosis. Up to our knowledge, the co-existence of bilateral carpal tunnel syndrome and familial Mediterranean fever has not been reported previously in the literature.
Subject(s)
Amyloid Neuropathies/complications , Carpal Tunnel Syndrome/etiology , Familial Mediterranean Fever/complications , Adult , Amyloid Neuropathies/diagnosis , Amyloid Neuropathies/surgery , Carpal Tunnel Syndrome/diagnosis , Carpal Tunnel Syndrome/surgery , Female , HumansABSTRACT
PURPOSE: The objective of this study was to investigate whether the retrobulbar hemodynamics in the ophthalmic (OA), posterior ciliary (PCA), central retinal (CRA), and vertebral (VA) arteries are affected in migraineurs without aura. METHODS: The eyes of migraineurs without aura and those of healthy control subjects were evaluated during both headache and headache-free periods. Retrobulbar and vertebral blood flow velocities in the OA, PCA, CRA, and the extracranial part of the VA were measured bilaterally using color Doppler sonography. The peak systolic and end-diastolic flow velocities and the pulsatility (PI) and resistance (RI) indices were determined for all arteries. RESULTS: In total, we enrolled 30 migraineurs and 31 healthy control subjects. Statistically significant differences between headache-free migraineurs and control subjects were observed in the PI and RI of both right and left PCAs and in the RI of both right and left CRAs. The PI and RI of the left VA of the migraineurs were significantly lower during both headache and headache-free periods than were those of the control subjects. Among the migraineurs, the peak systolic and end-diastolic velocities of the left VA were increased during headache periods relative to those found during the headache-free periods. CONCLUSIONS: The retrobulbar circulation and flow hemodynamics in the left VA may be altered in both headache and headache-free periods in migraineurs without aura. The differences found between migraineurs and control subjects may implicate autonomic dysfunction in migraineurs.
Subject(s)
Ciliary Arteries/diagnostic imaging , Migraine Disorders/physiopathology , Orbit/blood supply , Retinal Artery/diagnostic imaging , Ultrasonography, Doppler, Color , Vertebral Artery/diagnostic imaging , Adult , Analysis of Variance , Blood Flow Velocity , Case-Control Studies , Female , Humans , Middle AgedABSTRACT
Methylphenidate is commonly believed to lower seizure threshold. The safe use of methylphenidate has not been clarified in patients with attention-deficit hyperactivity disorder (ADHD) and concomitant active seizure or electroencephalographic (EEG) abnormalities. Patients with ADHD and active seizures (n = 57) and patients with ADHD and EEG abnormalities (n = 62), 6 to 16 years of age, were included in the study. The safety and efficacy of treatment with antiepilepsy drugs combined with methylphenidate were determined by assessing seizure frequency, changes in ADHD symptoms, the Conners' Rating Scales, EEG differences, and side effects. The Conners' Rating Scales, performed by parents and teachers, and mean total ADHD symptom scores at the beginning of the study and at the end were significantly different (P = .05 for the Conners' Rating Scales and P = .001 for ADHD symptom scores). Methylphenidate had a beneficial effect on EEG. Seizure frequency did not change from baseline. The side effects of methylphenidate were mild and transient Methylphenidate is safe and effective in children with ADHD and concomitant active seizures or EEG abnormalities.
Subject(s)
Attention Deficit Disorder with Hyperactivity/complications , Attention Deficit Disorder with Hyperactivity/drug therapy , Central Nervous System Stimulants/pharmacology , Epilepsy/complications , Epilepsy/drug therapy , Methylphenidate/pharmacology , Adolescent , Anticonvulsants/administration & dosage , Anticonvulsants/pharmacology , Child , Comorbidity , Electroencephalography , Female , Humans , Male , Treatment OutcomeABSTRACT
Vaccination against HBV is important in order to reduce the incidence of HBV infection. Although the HBV vaccine is among the safest of all vaccines, vaccination against HBV has been associated with side-effects. Herein we present a case of afebrile convulsion after recombinant HBV vaccination.
Subject(s)
Hepatitis B Vaccines/adverse effects , Seizures/etiology , Adult , Female , Hepatitis B virus/genetics , Humans , Vaccination , Vaccines, DNA/adverse effectsABSTRACT
The effect of azithromycin on bronchial hyperresponsiveness was measured in a group of 11 patients with mild asthma. Azithromycin 250 mg orally was administered intermittently to all the patients twice a week for eight weeks. The only other treatment was inhaled beta2 agonist, when required. A histamine inhalation test was performed at the beginning and at the fourth and the eighth week of the study. The mean PC20 values increased significantly over the initial value at the eighth week after the administration of azithromycin (p < 0.05) but mean values for FEV1 and FEV1 percent predicted did not differ significantly. These results suggested that eight weeks of intermittent, low-dose administration of azithromycin in patients with mild asthma might reduce the severity of bronchial hyperresponsiveness.